Paul Laland
Public Communications Contact bij PRINCIPIA BIOPHARMA INC.
Profiel
Paul Laland is currently working as a Media Contact at Principia Biopharma, Inc. He has previously worked as Co-Chairman at Fleishman-Hillard, Inc., Principal at Genentech, Inc. and Synergen, Inc., Vice President-Corporate Communications at VaxGen, Inc. and Novacea, Inc., Principal at Deltagen, Inc. and G.D.
Searle & Co., Inc., and Executive Vice President at WeissComm Partners, Inc. He also worked as a Media Contact at Astellas Gene Therapies, Inc.
Actieve functies van Paul Laland
Bedrijven | Functie | Begin |
---|---|---|
PRINCIPIA BIOPHARMA INC. | Public Communications Contact | - |
Eerdere bekende functies van Paul Laland
Bedrijven | Functie | Einde |
---|---|---|
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Public Communications Contact | 03-02-2009 |
AUDENTES THERAPEUTICS, INC. | Public Communications Contact | - |
DELTAGEN INC. | Corporate Officer/Principal | - |
G.D. Searle & Co., Inc.
G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Corporate Officer/Principal | - |
Synergen, Inc. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
DELTAGEN INC. | Commercial Services |
Bedrijven in privébezit | 9 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Synergen, Inc. | Utilities |
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
G.D. Searle & Co., Inc.
G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Process Industries |
Fleishman-Hillard, Inc.
Fleishman-Hillard, Inc. Miscellaneous Commercial ServicesCommercial Services Fleishman Hillard, Inc. is a strategic communications company. It provides public relations, public affairs and marketing communications services. The company was founded in 1946 and is headquartered in St. Louis, MO. | Commercial Services |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
WeissComm Partners, Inc.
WeissComm Partners, Inc. Miscellaneous Commercial ServicesCommercial Services WeissComm Partners, Inc. provides public relations and corporate communication services. It offers messaging and positioning, communications strategy, corporate and product communication, investor and media relation, issues and crisis management services. The company was founded by Jim Weiss in 2001 and is headquartered in San Francisco, CA. | Commercial Services |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |